Video

Taking a Closer Look at PCSK9 Part 3

Author(s):

As with any new class of medications there are many questions that will need to be answered by and for healthcare professionals.

As with any new class of medications there are many questions that will need to be answered by and for healthcare professionals. From costs to patient adherence, to overall usage PCSK9 promises to have long lasting effects on the medical community as a whole.

Jennifer Robinson, MD, MPH, from the University of Iowa addressed some of these questions during the American College of Cardiology Annual Scientific Sessions and Expo in San Diego.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.